A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1 1 Participating investigators: W. Berry, University of Colorado School of Medicine, Denver, CO; D. Kogut, Davis Community Hospital, Statesville, NC; G. Koval, St. Vincent Hospital and Medical Center, Portland, OR; D. Levine, University of Washington, Seattle, WA; D. Merrell, Riverside Hospital, Jacksonville, FL; R. Pruitt, University of Tennessee College of Medicine, Nashville, TN; D. Rex, Indiana University Hospital, Indianapolis, IN; D. Riff, Anaheim Memorial Hospital, Anaheim, CA; A. Rubin, University of Texas Health Science Center, Dallas, TX; D. Sales, Northwest Community Hospital, Arlington, IL; B. Salzberg, Saint Joseph’s Hospital, Atlanta, GA; E. Torres, University of Puerto Rico School of Medicine, San Juan, PR; L. Wruble, City of Memphis Hospital, Memphis, TN.
| Autor: | Levine, Douglas S.1,2, Riff, Dennis S.1,2, Pruitt, Ronald1,2, Wruble, Lawrence1,2, Koval, George1,2, Sales, David1,2, Bell, John K.1,2, Johnson, Lorin K.1,2 |
|---|---|
| Zdroj: | American Journal of Gastroenterology (Springer Nature). Jun2002, Vol. 97 Issue 6, p1398. 10p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|